Advertisement
Advertisement
KRYS
Krystal Biotech, Inc. Common Stock
268.96
USDSponsored
-10.61
-3.79%
Feb 04, 16:00 UTC -5
Closed
After-Market
269.15
+0.19
+0.07%
KRYS Earnings Reports
Positive Surprise Ratio
KRYS beat 18 of 33 last estimates.
55%
Next Report
Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
$107.56M
/$1.43
Implied change from Q3 25 (Revenue/ EPS)
+9.98%
/-46.24%
Implied change from Q4 24 (Revenue/ EPS)
+18.02%
/-5.92%
Krystal Biotech, Inc. Common Stock earnings per share and revenue
On Nov 03, 2025, KRYS reported earnings of 2.66 USD per share (EPS) for Q3 25, beating the estimate of 1.10 USD, resulting in a 140.22% surprise. Revenue reached 97.80 million, compared to an expected 95.05 million, with a 2.89% difference. The market reacted with a +0.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of 1.43 USD, with revenue projected to reach 107.56 million USD, implying an decrease of -46.24% EPS, and increase of 9.98% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Mesoblast Limited - ADR
Report Date
Jan 29, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.07
Surprise
-5.90%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.82
Actual
$11.44
Surprise
+5.65%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were Krystal Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Krystal Biotech, Inc. Common Stock reported EPS of $2.66, beating estimates by 140.22%, and revenue of $97.80M, 2.89% above expectations.
How did the market react to Krystal Biotech, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 0.17%, changed from $197.51 before the earnings release to $197.85 the day after.
When is Krystal Biotech, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 02, 2026.
What are the forecasts for Krystal Biotech, Inc. Common Stock's next earnings report?
Based on 12
analysts, Krystal Biotech, Inc. Common Stock is expected to report EPS of $1.43 and revenue of $107.56M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement